Effectiveness of ustekinumab in postoperative Crohn's disease management: Evidence from a Chinese multicenter cohort

Figure 3 Ustekinumab safety profile in postoperative Crohn's disease. A: Bar chart comparing the adverse event (AE) rates between the first-line and second-line ustekinumab treatment groups, showing comparable safety profiles; B: Pie chart detailing the distribution of AE types among the seven reported events, including upper respiratory infection, renal impairment, liver function abnormality, and hand numbness. All of the AEs were mild to moderate in severity. UST: Ustekinumab.